IGCS 2022 - Annual Global Meeting of the International Gynecologic Cancer
Sep 29 - Oct 01, 2022 | New YorkNYUS
LARVOL is not affiliated with Annual Global Meeting of the International Gynecologic Cancer and all trademarks, logos, and brand names are property of their respective owners
Showing 79 abstracts linked to Trials
DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL
COMPARATIVE EFFECTIVENESS OF HIPEC FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY: MULTICENTER, PROSPECTIVE, COHORT STUDY (KGOG 3042)
SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ARIEL4 STUDY OF RUCAPARIB VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED, RELAPSED OVARIAN CARCINOMA AND A DELETERIOUS BRCA1/2 MUTATION
CLINICAL BENEFIT OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER PATIENTS WITH HIGH FOLATE RECEPTOR ALPHA EXPRESSION: RESULTS FROM THE SORAYA STUDY
MIRVETUXIMAB SORAVTANSINE AND BEVACIZUMAB IN FOLATE RECEPTOR ΑLPHA-POSITIVE OVARIAN CANCER: EFFICACY IN PATIENTS WITH AND WITHOUT PRIOR BEVACIZUMAB
MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: PATIENT-REPORTED OUTCOMES FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL
ATEZOLIZUMAB AND BEVACIZUMAB IN RECURRENT ENDOMETRIAL CANCER: A PHASE II, MULTI INSTITUTIONAL TRIAL
SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL BY NUMBER OF PRIOR LINES OF CHEMOTHERAPY IN PATIENTS WITH BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER RECEIVING OLAPARIB TREATMENT OR NON-PLATINUM CHEMOTHERAPY IN SOLO3
OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA
SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL (OS) AT 7-YEAR (Y) FOLLOW-UP (F/U) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (OC) AND A BRCA MUTATION (BRCAM) WHO RECEIVED MAINTENANCE OLAPARIB IN THE SOLO1/GOG-3004 TRIAL
MIRVETUXIMAB SORAVTANSINE AND CARBOPLATIN FOR TREATMENT OF PATIENTS WITH RECURRENT FOLATE RECEPTOR ALPHA-POSITIVE PLATINUM-SENSITIVE OVARIAN CANCER: A FINAL ANALYSIS
POST-HOC ANALYSIS OF OBJECTIVE RESPONSE RATE BY MISMATCH REPAIR PROTEIN DIMER LOSS/MUTATION STATUS IN PATIENTS WITH MISMATCH REPAIR DEFICIENT ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB
UPDATED SAFETY OF LENVATINIB + PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775
SEMINAL ABSTRACT PRESENTATION: ATHENA–MONO (GOG-3020/ENGOT-OV45): A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL EVALUATING RUCAPARIB MONOTHERAPY VS PLACEBO AS MAINTENANCE TREATMENT FOLLOWING RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER
SEMINAL ABSTRACT PRESENTATION: FINAL OVERALL SURVIVAL (OS) RESULTS FROM THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL EVALUATING MAINTENANCE OLAPARIB (OLA) PLUS BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC)